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Abstract
Background: Locally advanced rectal cancer (LARC) comprises heterogeneous tumours with predominant hypoxic
components. The hypoxia-inducible metabolic shift causes microenvironmental acidification generated by carbonic
anhydrase IX (CAIX) and facilitates metastatic progression, the dominant cause of failure in LARC.
Methods: Using a commercially available immunoassay, circulating CAIX was assessed in prospectively archived
serial serum samples collected during combined-modality neoadjuvant treatment of LARC patients and correlated
to histologic tumour response and progression-free survival (PFS).
Results: Patients who from their individual baseline level displayed serum CAIX increase above a threshold of 224 pg/
ml (with 96 % specificity and 39 % sensitivity) after completion of short-course neoadjuvant chemotherapy (NACT)
prior to long-course chemoradiotherapy and definitive surgery had significantly better 5-year PFS (94 %) than patients
with below-threshold post-NACT versus baseline alteration (PFS rate of 56 %; p < 0.01). This particular CAIX parameter,
ΔNACT, was significantly correlated with histologic ypT0–2 and ypN0 outcome (p < 0.01) and remained an
independent PFS predictor in multivariate analysis wherein it was entered as continuous variable (p = 0.04).
Conclusions: Our results indicate that low ΔNACT, i.e., a weak increase in serum CAIX level following initial
neoadjuvant treatment (in this case two cycles of the Nordic FLOX regimen), might be used as risk-adapted
stratification to postoperative therapy or other modes of intensification of the combined-modality protocol in LARC.
Trial registration: ClinicalTrials.gov NCT00278694
Keywords: Carbonic anhydrase IX, Chemotherapy, Metastasis, Radiotherapy, Rectal cancer, Survival, Tumour
microenvironment
Background
Locally advanced rectal cancer (LARC) comprises hetero-
geneous tumours with hypoxic components, growing with
locally advanced disease manifestations within the pelvic
cavity. With contemporary treatment, commonly includ-
ing fluoropyrimidine-based chemoradiotherapy (CRT)
followed by resection of the residual tumour within its en-
tire extension, local recurrence rates are low [1]. To the
contrary, development of metastatic disease has
remained the dominant cause of failure, typically re-
ported to be 30–40 % of cases in recent clinical trials
[2, 3]. Consequently, in the past decade, it has been
increasingly appreciated that the sequence and combination
of the various treatment modalities should be revamped. In
October 2005, we launched a prospective non-randomised
study composed of neoadjuvant oxaliplatin-containing
chemotherapy (NACT; two cycles of the Nordic FLOX
regimen) [4] before long-course CRT and radical surgery in
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order to intensify neoadjuvant LARC treatment, hypothe-
sising such an approach might counteract the aggressive
biology that evolves within the hostile microenviron-
ment of hypoxic tumour components.
Hypoxia, causing metabolic changes towards enhanced
glycolysis, is an important feature of the tumour micro-
environment [5]. Additionally, the malignant phenotype
promotes aerobic glycolysis as a consequence of dimin-
ished mitochondrial oxidative phosphorylation [6]. Tu-
mours with such attributes rely on robust pH-regulating
systems to combat the resulting excessive generation of
lactic and carbonic acids [7]. Among these is the
tumour-specific carbonic anhydrase IX (CAIX), a trans-
membrane enzyme that regulates extracellular and intra-
cellular pH by catalysing the reversible hydration of
carbon dioxide to bicarbonate and protons [8].
Accordingly, as demonstrated in a number of tumour
types, CAIX over-expression is linked to poor prognosis.
This observation has been attributed to the microenviron-
mental acidification that is generated by CAIX, causing
breakdown of the extracellular matrix via proteinase acti-
vation and growth factor stimulation of cancer-associated
fibroblasts, and consequently, augmentation of the meta-
static potential [9, 10]. Moreover, the extracellular domain
of the CAIX protein can be released from the cell surface
by proteolytic cleavage [11]. In the present study, we asked
whether CAIX, as retrieved in the circulation of LARC pa-
tients, might function as indicator of therapeutic outcome.
Specifically, we employed prospectively archived serial
serum samples collected during the neoadjuvant treat-
ment course of our study patients, recognising the present
follow-up time of five years for the vast majority of the
cases, which would allow robust outcome analysis.
Methods
Patients and treatment
The study protocol was approved by the Institutional
Review Board of the Norwegian Radium Hospital and
the Regional Committee for Medical and Health Re-
search Ethics, and was in accordance with the Helsinki
Declaration. Written informed consent was required for
participation. The patient population of 66 cases within
the current analysis of serum CAIX was enrolled from
October 5, 2005 through November 11, 2009. Patient
eligibility criteria, evaluation procedures and review pro-
cedures of follow-up have been described in detail previ-
ously [12]. The treatment protocol consisted of two
cycles of NACT (the Nordic FLOX regimen: oxalipla-
tin 85 mg/m2 on day 1 and daily bolus fluorouracil
500 mg/m2 and folinic acid 100 mg on days 1 and 2
every second week) followed by CRT. Radiation was
delivered in daily 2-Gy fractions five days per week
over a 5-week period. During the radiotherapy course,
concomitant chemotherapy was given as oxaliplatin
50 mg/m2 once weekly and capecitabine 825 mg/m2
twice daily on days of radiotherapy. Surgery was
planned 6–8 weeks after completion of the neoadju-
vant treatment. In accordance with national guide-
lines, patients did not proceed to further treatment
after surgery.
Serum sampling
From the 66 study cases, serum had been collected at
baseline (n = 66), at CRT commencement immediately
following the two cycles of NACT (denoted post-NACT;
n = 66), at CRT completion on the day of the 25th radi-
ation fraction (denoted post-CRT; n = 54) and at evalu-
ation of the neoadjuvant therapy four weeks after CRT
completion (n = 50). The collection, processing and stor-
age of samples followed a standardised protocol, where
blood was drawn in plain serum tubes with no anti-
coagulants for centrifugation to separate serum, which
was left on ice for no more than one hour before storage
at –80 °C. The analysis of serum CAIX was undertaken
in June–July 2014 (i.e., after 55–105 months of storage).
Assessment of serum CAIX
This analysis was undertaken with the Quantikine®
Human CA9 Immunoassay (R&D Systems, Minneap-
olis, MN, USA) according to the manufacturer’s
manual. Briefly, 100 μl of sample and standard con-
trol samples provided with the assay were incubated
on microtiter plates that were pre-coated with a
monoclonal antibody specific for CAIX. This was
followed by incubation with an enzyme-linked poly-
clonal antibody against CAIX. A substrate solution
containing a dye was added and colour intensity was
measured by a microplate reader (Modulus™ Micro-
plate Multimode Reader; Turner BioSystem, Sunny-
vale, CA, USA). To correct for optical imperfections,
plate readings at 540 nm were subtracted before the
CAIX concentration was estimated from the stand-
ard curve and retrieved as pg/ml for each measure-
ment. Assay performance was evaluated by plate-to-
plate variation measures from patient samples within
the high, medium and low range of CAIX levels,
providing a coefficient of variation (CV) of 6.8 % in
average for all of the three sample groups (specific-
ally, CV = 5.7 % for the high level group, CV = 5.5 %
for the medium level group and CV = 9.2 % for the
low level group). Each of the individual serum sam-
ples was analysed in duplicate and the mean value
was used in further calculations. For patients with
paired sample measurements of post-NACT versus
baseline (ΔNACT; n = 66) and post-CRT versus base-
line (ΔCRT; n = 54), changes in the absolute value of
serum CAIX following NACT alone or the combin-
ation of NACT and CRT were also calculated.
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Study endpoints
The resected tumour specimens were histologically eval-
uated for treatment response according to standard sta-
ging (ypTN). In this patient population of locally
advanced tumours (mainly T3–4 cases), ypT0–2 out-
come was considered as good response and correspond-
ingly, ypT3–4 results were regarded as poor tumour
shrinkage. Moreover, histologic tumour regression grade
(TRG) was determined. In this, TRG1 represents ab-
sence of residual tumour cells (pathologic complete re-
sponse), TRG2 corresponds to sparsely remaining
tumour cells scattered throughout fibrosis (near-
complete response), TRG3 shows residual tumour cells
in fibrosis, TRG4 defines residual tumour cells outgrow-
ing fibrosis and TRG5 refers to the absence of morpho-
logic signs of treatment response (no fibrosis) [13]. Of
note, when responding to neoadjuvant treatment, LARC
frequently shows fragmentation into microscopic re-
sidual disease [14]. Consequently, it is rational to group
TRG2 together with TRG1 as good histologic regression
and correspondingly, the range of TRG3–5 scores as
poor tumour cell response. Patients were scheduled for
five years of follow-up after surgery. The clinical end-
point was progression-free survival (PFS). The present
follow-up data was censored on August 8, 2013.
Statistical analysis
All analyses were performed using IBM SPSS Statistics
for Windows, Version 22.0 (IBM Corp., Armonk, NY,
USA) or SigmaPlot 12.5 (Sysat Software Inc., Chicago,
IL, USA). Continuous data were described with median
and range and compared using non-parametric Mann-
Whitney U-test, while categorical variables were de-
scribed with proportions and percentages and compared
using Pearson’s chi-square or Fisher’s exact tests. Diag-
nostic accuracy was assessed by receiver-operating char-
acteristic (ROC) analysis. Estimated 5-year PFS was
calculated from the time of study enrolment to the date
of recurrent disease (diagnosis of local recurrence or dis-
tant metastasis), death of any cause or end of follow-up
(five years after the date of surgery), whichever came
first. Crude differences in survival were assessed using
the Kaplan-Meier method and log-rank test. Associa-
tions between selected variables and PFS were modelled
with univariate and multivariate Cox regression analysis.
The results were expressed as hazard ratio with 95 %
confidence interval. Variables that were statistically sig-
nificant in univariate regression were entered into the
multivariate model, but owing to limited statistical
power, no more than three variables were included in
the final model. The assumption of proportional hazards
was tested by visual inspection of log-minus-log plots.
All tests were two-sided. p-values less than 0.05 were
considered statistically significant.
Results
Serum CAIX and clinical outcome
Figure 1 illustrates the measured CAIX levels in serum
samples from the patients that were present in the current
study analysis. From a median baseline level of 63 pg/ml
(range 17–591; n = 66), the median post-NACT value had
increased to 213 pg/ml (range 59–875; n = 66) with fur-
ther rise to 309 pg/ml (range 48–1226; n = 54) in the post-
CRT samples. At evaluation, the median serum CAIX level
had fallen to 80 pg/ml (range 34–429; n = 50). All group
measurements within the neoadjuvant treatment course
were significantly different from baseline.
Each individual CAIX dataset was divided in two
groups above and below median value for further ana-
lysis (Additional file 1: Table S1). Statistical correlation
was found between the clinical endpoint (PFS) and the
absolute level of serum CAIX at NACT completion only
and not for any of the other sampling points. But since
both the post-NACT and post-CRT sampling points im-
mediately followed the completion of a defined thera-
peutic modality, we further investigated whether the
individual patient’s serum CAIX response (i.e., relative to
baseline) at each of the sampling points might predict re-
sponse to the combined-modality therapy in terms of dis-
ease outcome. Here, ΔNACT (median value 138 pg/ml,
range from –4 to 659; n = 66) and ΔCRT (median value
208 pg/ml, range from –90 to 1022; n = 54) were as-
sumed to reflect the change in serum CAIX following
Fig. 1 Serum carbonic anhydrase IX (CAIX) levels during neoadjuvant
treatment of patients with locally advanced rectal cancer. Using a
commercially available immunoassay, CAIX was measured in serum
sampled from the study patients at baseline (n = 66), following four
weeks of neoadjuvant chemotherapy (post-NACT; n = 66), at
completion of a 5-week course of chemoradiotherapy (post-CRT;
n = 54) and at evaluation of the neoadjuvant therapy four weeks
later (n = 50). CAIX values are depicted by boxes (25th, 50th and
75th percentiles), bars (10th and 90th percentiles) and circles
(outlier values). Distribution of CAIX values during the neoadjuvant
course was different from baseline (* p < 0.05, ** p < 0.001;
calculated by Mann-Whitney U-test)
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NACT alone or the entire treatment course of NACT
and CRT, respectively. No correlation was found be-
tween ΔCRT and PFS.
For PFS prediction, an optimum ΔNACT threshold of
224 pg/ml was found by ROC analysis (Additional file 2:
Figure S1; area under curve 0.74, confidence interval
0.61–0.87; p < 0.01), yielding 96 % specificity, 39 % sensi-
tivity, 94 % (17 of 18) positive predictive value and 44 %
(21 of 48) negative predictive value. Estimated 5-year
PFS was 94 % and 56 % when separating the patients
above and below the ΔNACT threshold (p < 0.01)
(Fig. 2).
ΔNACT and tumour responses
Since ΔNACT values seemed to be a predictor of the re-
sultant effect of the combined-modality treatment, fur-
ther exploration of study endpoints was undertaken with
this variable. Patient and tumour characteristics are
given in Table 1. The two groups of patients with
ΔNACT values above and below the estimated threshold
were balanced (i.e., showed no statistical differences)
with regard to baseline tumour characteristics.
Significant correlation was found between ΔNACT and
the histologic tumour stage following the neoadjuvant
therapy, as patients with serum CAIX increase above
224 pg/ml had significantly higher rates of ypT0–2 and
ypN0 outcome (p < 0.01). Of note, ΔNACT did not cor-
relate with histologic TRG score. One of the 66 patients
had disease progression in the pelvic cavity during the
neoadjuvant treatment and therefore proceeded to pallia-
tive surgery. As a consequence, histologic tumour re-
sponse data were missing and the single case was omitted
from analysis.
ΔNACT in PFS prediction
When last censored, the median follow-up time of this
specific cohort of 66 patients was 63 months (range 3–
65). Of these, 22 patients had experienced disease relapse;
three had local recurrence and 19 had metastatic progres-
sion as the first event. As seen from Table 2, amongst
baseline variables, young age and T4 stage were signifi-
cantly associated with poorer PFS. In this univariate ana-
lysis, ΔNACT was entered as continuous data, and again
the higher the value the better PFS. As expected, histo-
logic treatment response was highly associated with clin-
ical outcome, underpinned by the significant correlations
of both ypT3–4 and ypN1–2 stages as well as TRG3–5
scores with adverse PFS. In multivariate analysis, into
which only variables either present at baseline or during
the neoadjuvant treatment were entered, the parameter
requiring initiation of therapy (ΔNACT) was the only one
that remained significantly associated with PFS (p = 0.04)
(Additional file 3: Table S2).
Discussion
The present study of circulating CAIX response during
neoadjuvant treatment of LARC presented novel find-
ings. Patients who from their individual baseline level
showed strong increase in serum CAIX after completion
of a relatively short course of NACT prior to long-
course CRT had significantly better PFS than patients
with low post-NACT versus baseline alteration. This par-
ticular CAIX parameter, ΔNACT, remained the only in-
dependent PFS predictor in multivariate analysis of
variables presenting either at baseline or during the neo-
adjuvant treatment. Strikingly, high ΔNACT was signifi-
cantly correlated with ypT0–2 and ypN0 outcomes after
the full neoadjuvant treatment. In contrast, ΔNACT and
histologic TRG score of the surgical specimen were un-
related parameters. Hence, in this population of mainly
T3–4 rectal cancer patients, a strong serum CAIX re-
sponse to initial treatment reflected forthcoming tumour
down-staging (ypT0–2) and node sterilisation (ypN0),
but not necessarily tumour cell death (TRG score), and
ultimately a favourable PFS.
In this study, the number of cases from whom serum
samples were available was rather small (ranging from
66 at baseline to 50 before surgery) with only 22 patients
Fig. 2 Serum carbonic anhydrase IX (CAIX) levels and progression-
free survival in locally advanced rectal cancer. Progression-free
survival was analysed (by the Kaplan-Meier method) for the
population of 66 study patients with paired serum sample
measurements of CAIX following neoadjuvant induction
chemotherapy versus baseline (a variable termed ΔNACT), divided
into two groups above (solid line) and below (dashed line) an
estimated optimum cut-off ΔNACT value of 224 pg/ml.
Difference between the two groups was significant (p < 0.01)
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had reported a PFS event. Consequently, the value of
multivariate regression analysis was limited. The study
findings should ideally have been evaluated in an inde-
pendent patient cohort where cases had undergone
combined-modality radiotherapy with curative intent for
a locally advanced malignancy along the simultaneous
prospective serial sampling of serum (or plasma)
throughout the treatment course and where, addition-
ally, short-term (tumour response) and long-term (PFS
or an equivalent main event) outcome data were avail-
able. Our attempts to identify such a material have not
been successful.
In rectal cancer, a limited number of studies have re-
ported CAIX expression analysed by immunohistochem-
istry in surgical specimens from patients undergoing
primary surgery [15–17] or in baseline biopsy samples
or surgical specimens from patients given neoadjuvant
therapy [16, 18, 19]. Interestingly, patients who obtained
weak CAIX staining in surgical specimens after neoadju-
vant short-course (radiation) or long-course treatment
had significantly better disease-specific survival than pa-
tients with resulting strong CAIX tumour expression
[16]. The authors also divided the long-course group
into patients that had been given CRT or radiation only
and found significantly higher percentage of high CAIX
expression in surgical samples from patients that had
not received concomitant chemotherapy; of note, the
radiotherapy only group consisted of only eight cases.
Still, it was contended that chemotherapy, which in this
case was fluoropyrimidine-based regimens, might im-
prove tumour oxygenation and the final patient outcome
[16].
To our knowledge, the present study is the first to re-
port on the profile of circulating CAIX during neoadju-
vant treatment in LARC. Conceptually, serum CAIX
levels at the post-NACT and post-CRT sampling points
reflected the contribution of either NACT or NACT
followed by CRT within the entire combined-modality
protocol. To our initial surprise, ΔNACT but not ΔCRT
appeared to be a predicting factor of PFS. Hence, the
Table 1 Study patients’ characteristics
All patients ΔNACT ΔNACT p-value
<224 pg/ml >224 pg/ml
(n = 66) (n = 48) (n = 18)
n (%) n (%) n (%)
Median age (range), years 59 (30–73) 57 (30–72) 61 (50–73) 0.0281
Gender Male 38 (58) 28 (58) 10 (56) 0.842
Female 28 (42) 20 (42) 8 (44)
TN stage T2–3 45 (68) 31 (65) 14 (78) 0.312
T4 21 (32) 17 (35) 4 (22)
N0–1 16 (24) 10 (21) 6 (33) 0.353
N2 49 (75) 37 (77) 12 (67)
ND 1 1 0
Baseline CEA level ≤ULN 38 (58) 25 (52) 13 (72) 0.142
>ULN 28 (42) 23 (48) 5 (28)
Baseline haemoglobin level ≥LLN 54 (82) 39 (81) 15 (83) 13
<LLN 12 (18) 9 (19) 3 (17)
ypTN stage ypT0–2 37 (56) 22 (46) 15 (83) 0.0082
ypT3–4 28 (42) 25 (52) 3 (17)
ND 1 1 0
ypN0 46 (70) 29 (60) 17 (94) 0.0092
ypN ypN1–2 19 (29) 18 (38) 1 (6)
ND 1 1 0
TRG score TRG1–2 44 (67) 30 (63) 14 (78) 0.282
TRG3–5 21 (32) 17 (35) 4 (22)
ND 1 1 0
The population of 66 study patients with paired serum sample measurements of carbonic anhydrase IX following neoadjuvant induction chemotherapy versus
baseline (a variable termed ΔNACT) was divided into two groups above and below an estimated optimum cut-off ΔNACT value of 224 pg/ml. Distribution of
parameters between the two groups was compared using 1: Mann-Whitney U-test, 2: Pearson’s chi-square test or
3: Fisher’s exact test
ND not determined (omitted from analysis), CEA carcinoembryonic antigen, ULN upper limit of normal, LLN lower limit of normal, TRG tumour regression grade
Hektoen et al. BMC Cancer  (2015) 15:543 Page 5 of 8
impact of two cycles of Nordic FLOX but not full treat-
ment with NACT and CRT on tumour release of CAIX
into the circulation seemed to be critical for the ultimate
outcome. Patients with increase in serum CAIX of more
than 224 pg/ml from the baseline level were more likely
to obtain tumour down-staging and node sterilisation,
which is recognised to translate into long-term survival
benefits [20]. It is further noteworthy that the TRG out-
come, which represents the degree of surviving tumour
cells relative to fibrosis (i.e., histologically responding
tumour components) in the surgical specimen, was sta-
tistically unrelated to ΔNACT.
A reasonable interpretation of the two observations
might be that a response of CAIX-expressing stromal cells
to the initial therapy would be conditional for an excellent
PFS (in this case, an estimated 5-year rate of 94 %). In this
context, an interesting report published by pathologists
looked at tumour CAIX expression in more than one hun-
dred patients who had undergone primary surgery for
colorectal carcinoma [15]. Intriguingly, CAIX expression
was demonstrated both in tumour epithelial cells (78 % of
cases) and tumour-associated stromal cells (37 % of cases),
and half of cases that lacked epithelial CAIX expression
were positive for stromal staining. Of particular note,
whereas epithelial CAIX expression had no impact on sur-
vival outcome, stromal positive patients had significantly
poorer overall survival, and this remained an independent
prognostic factor in multivariate analysis. The role of
CAIX-expressing stromal cells on clinical outcome has
also been highlighted in breast, lung and head-and-neck
carcinoma [21–23].
With reference to interpretation of findings mentioned
above [16] as well as to the data from the present study,
it is tempting to speculate about the mechanistic role of
chemotherapy in shedding of the CAIX protein. In our
study, induction chemotherapy in terms of two cycles of
the Nordic FLOX regimen was introduced in order to
intensify the multimodal treatment protocol, hypothesis-
ing such an approach might counteract the aggressive
biology of a hypoxic tumour microenvironment with the
ultimate aim of improving long-term survival. The mi-
croenvironmental acidification generated by CAIX in-
duces metalloproteinase activation [10], which next
causes proteolytic CAIX cleavage and consequently its
ectodomain shedding [11]. Furthermore, experimental
data supports the notion that chemotherapy may en-
hance such shedding [11]. One might therefore speculate
that chemotherapy specifically targets hypoxic, CAIX-
expressing tumour components. However, it remains un-
clear whether the ΔNACT response observed in the
present study was contingent on the Nordic FLOX regi-
men as such or whether an early CAIX response, irre-
spective of the therapeutic modality, would have
correlated with a favorable long-term outcome. In the
forthcoming, concerns and implications for excisting
clinical practice will be discussed.
Despite contemporary multimodal therapy, a substan-
tial number of rectal cancer patients will experience
metastatic dissemination. None of the recently published
randomised trials on combined-modality treatment of
LARC has demonstrated survival benefit [24]. Like our
study, one strategy that has been argued to improve cure
rate would be to introduce systemic therapy within the
neoadjuvant treatment course to eradicate occult micro-
metastases that might already exist at the presentation
of the local disease. Induction chemotherapy involving
oxaliplatin has been included in several previous neoad-
juvant LARC trials [25–31]. However, it has been a con-
cern that sequential treatment causes protraction of the
total treatment time, which is undesirable in terms of
delaying commencement of radiation as a well-
documented modality to eliminate the source of clono-
genic tumour cells with metastatic potential. Additionally,
in this context, the administration of NACT might influ-
ence patient compliance with subsequent CRT and the ef-
ficacy of CRT, in particular the possibility that NACT
might select for radioresistant tumour clones. To comply
with these concerns, our strategy was to administer
NACT limited to only two cycles of the Nordic FLOX
regimen before CRT and definitive surgery.
Our subsequent CRT regimen involved concomitant
oxaliplatin and the fluoropyrimidine analogue capecitabine.
Table 2 Progression-free survival in locally advanced rectal
cancer
HR1 95 % CI p-value
ΔNACT 0.994 (0.990–0.999) 0.01
Age 0.953 (0.914–0.993) 0.02
TN stage T2–3
T4 2.71 (1.17–6.27) 0.02
N0–1
N2 1.22 (0.449–3.30) 0.70
Baseline CEA level ≤ULN
>ULN 1.85 (0.799–4.29) 0.15
ypTN ypT0–2
ypT3–4 6.10 (2.22–16.7) <0.001
ypN0
ypN1–2 2.84 (1.20–6.70) 0.02
TRG score TRG1–2
TRG3–5 3.00 (1.27–7.08) 0.01
Adjusted hazard ratio (HR) with 95 % confidence interval (CI) was calculated
by univariate Cox regression analysis for each of the indicated variables
ΔNACT paired serum sample measurements of carbonic anhydrase IX following
neoadjuvant induction chemotherapy versus baseline, CEA carcinoembryonic
antigen, ULN upper limit of normal, TRG tumour regression grade
1: HR less than 1 indicates that patients had higher probability of favourable
progression-free survival
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The role of oxaliplatin as an additional component of CRT
in LARC is controversial. During the conduct of our trial,
emerging data from three different randomised studies
suggested no additional clinical benefit but signifi-
cantly enhanced acute toxicity of adding oxaliplatin to
fluoropyrimidine-based CRT [2, 32–34], whereas a
fourth study demonstrated significantly improved rate
of histologic complete response in the oxaliplatin-
supplemented group [35].
Within this frame of reference, it is noteworthy that
a strong serum CAIX response to the two FLOX cy-
cles translated into an advantageous PFS. Assuming
that CAIX is a tumour-specific protein that is re-
leased into the circulation as a direct response to
therapy [11], i.e., that no other tissue of origin con-
tributes as a toxic response to the given therapy, the
absolute change in serum CAIX level might be uti-
lised in risk-adapted individualisation of LARC treat-
ment. Currently, the use of postoperative adjuvant
chemotherapy, as being given in colon cancer, has
been adopted at a number of centres internationally
despite the lack of evidence-based research on which
to base treatment decisions [1, 36]. In most Nordic
countries, postoperative treatment of rectal cancer is
offered only on specific, individual-based indications.
Circulating CAIX response to the initial therapy, as
biomarker for systemic risk assessment, might assist
in stratification of refractory cases to postoperative
treatment, which might be conventional chemotherapy
or targeted therapeutics directed towards hypoxic
tumour mechanisms.
Conclusion
Our results suggest that a strong serum CAIX response
to initial neoadjuvant treatment in LARC reflects forth-
coming tumour down-staging and node sterilisation and
might be used as risk-adapted stratification to adjusted
multimodal treatment protocols.
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